XSHE003020
Market cap462mUSD
Jan 09, Last price
17.88CNY
1D
-1.32%
1Q
-3.56%
IPO
-17.53%
Name
Hefei Lifeon Pharmaceutical Co Ltd
Chart & Performance
P/E
14.98
P/S
1.79
EPS
1.19
Div Yield, %
1.81%
Shrs. gr., 5y
11.12%
Rev. gr., 5y
5.94%
Revenues
1.90b
-26.31%
Net income
227m
+8.33%
CFO
204m
+1.51%
Dividend
May 28, 20240.6 CNY/sh
Profile
Hefei Lifeon Pharmaceutical Co., Ltd. engages research, development, production, and sales of pharmaceutical preparations and an active ingredient (APIs). It offers APIs, such as succimer, urea, paeonol, felodipine, doxazosin mesylate, zofenopril calcium, troxerutin, and sodium 2,3-dimercapto-1-propanesulfonate; medicinal preparations comprising felodipine sustained release tablets, doxazosin mesylate extended-release tablets, melbinum glipizide tablet, yiqihewei capsule, kunning granule, armillariella oral solution, paeonol ointment, urea and vitamin e cream, Kecuo Yintong gel, and Compound Golden Larch bark gel; and plant extracts, including clove oil, evening primrose oil, herba clinopodii P.E, quercetin, and dihydroquercetin. The company also operates retail chain of pharmaceuticals. Hefei Lifeon Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Hefei, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 1,900,789 -26.31% | 2,579,340 13.46% | ||||||
Cost of revenue | 1,558,584 | 2,320,850 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | 342,205 | 258,490 | ||||||
NOPBT Margin | 18.00% | 10.02% | ||||||
Operating Taxes | 23,534 | 30,216 | ||||||
Tax Rate | 6.88% | 11.69% | ||||||
NOPAT | 318,671 | 228,274 | ||||||
Net income | 226,673 8.33% | 209,249 21.50% | ||||||
Dividends | (61,282) | (64,848) | ||||||
Dividend yield | 1.14% | 1.67% | ||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 10,033 | |||||||
Long-term debt | 36,699 | 6,760 | ||||||
Deferred revenue | 20,164 | 12,979 | ||||||
Other long-term liabilities | 1 | 1,160 | ||||||
Net debt | (733,757) | (640,185) | ||||||
| Cash flow | ||||||||
Cash from operating activities | 203,675 | 200,638 | ||||||
CAPEX | (197,538) | |||||||
Cash from investing activities | (440,600) | |||||||
Cash from financing activities | 36,625 | |||||||
FCF | 98,334 | 122,814 | ||||||
| Balance | ||||||||
Cash | 564,449 | 642,695 | ||||||
Long term investments | 206,008 | 14,283 | ||||||
Excess cash | 675,417 | 528,011 | ||||||
Stockholders' equity | 1,260,616 | 960,849 | ||||||
Invested Capital | 1,252,101 | 952,078 | ||||||
ROIC | 28.92% | 25.35% | ||||||
ROCE | 17.63% | 17.45% | ||||||
| EV | ||||||||
Common stock shares outstanding | 191,560 | 156,562 | ||||||
Price | 28.15 13.30% | 24.85 -8.44% | ||||||
Market cap | 5,392,409 38.62% | 3,889,952 -8.44% | ||||||
EV | 4,846,623 | 3,249,767 | ||||||
EBITDA | 389,548 | 294,526 | ||||||
EV/EBITDA | 12.44 | 11.03 | ||||||
Interest | 1,400 | 890 | ||||||
Interest/NOPBT | 0.41% | 0.34% | ||||||